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Tattoos and coincidental skin conditions: the
example of lymphomatoid papulosis
DOI: 10.1111/bjd.13120
DEAR EDITOR, I read with interest the recent report by Haus
et al.
1 about a patient who developed two lesions of lympho-
matoid papulosis (LyP) on the red parts of a tattoo. However,
their report deserves a few comments. Many reported pseudo-
lymphomas on tattoos involve T cells or both T and B cells,
and are not attributed ‘mainly’ to B cells, as described in the
manuscript.
2,3 To date, Sangueza et al.
4 in 1992 have pub-
lished the only well-documented report of the malignant
transformation of a T-cell pseudolymphoma into a monoclonal
B-cell lymphoma related to a chronic tattoo reaction.
It is widely accepted that mercury has disappeared from red
ink manufacturing.
5 Despite withdrawal of mercury, red tattoo
reactions, including pseudolymphoma, still occur, raising the
question of the culprit component or by-product leading to
such reactions. Beyond the nosological issues that the authors
try to discuss (LyP or pseudolymphoma), the present case
illustrates an increasingly frequent situation due to the popu-
larity of tattoos, namely the occurrence of coincidental derma-
tological conditions in tattooed individuals. Indeed, in the vast
majority of cases of both pseudolymphoma and other ‘allergic’
reactions, tattoos display either a complete inﬁltration of the
whole culprit colour or an inﬁltration made by more or less
distinct papules or nodules restricted to one colour.
2,3 A tattoo
‘allergy’ does not present as one, two or three single lesions
on a very little part of the culprit colour. It is hard to conceive
that a chronic stimulation of a clonal subset of lymphocytes
against a speciﬁc component of the colour would be responsi-
ble for only an extremely limited reaction on two distant parts
of such a wildly coloured area as reported by Haus et al.
Besides, despite being rare, localized LyP happens more often
among the young.
6
It seems rather likely that this patient developed a localized
LyP on a fortuitous tattooed area. One could argue the possi-
ble presence of speciﬁc impurities located speciﬁcally on both
areas that could have selected a monoclonal population, but it
is pushing the speculation rather far, especially as the reaction
spontaneously resolved after 2 months and the patient has
now been disease free for the past 15 years. Pseudolympho-
mas on tattoos may indeed regress spontaneously,
2 but they
usually follow a protracted course in the absence of any treat-
ment. The number of anecdotal reactions on tattoos
7 will keep
on increasing with the popularity of tattoos and the ageing of
the tattooed population, due to a fortuitous coexistence of a
skin condition and the tattoo. LyP on a tattoo seems to be one
of them.
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Association of hidradenitis suppurativa disease
severity with increased risk for systemic
comorbidities
DOI: 10.1111/bjd.13122
DEAR EDITOR, Hidradenitis suppurativa (HS), also known as
acne inversa, is a chronic, inﬂammatory skin disease affect-
ing terminal hair follicles in apocrine-gland-bearing skin.
1
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All patients,
n = 154
HS severity
High disease
burden, n = 60
Medium disease
burden, n = 94
Demographics
Age (years), mean  SD 363  1176 372  1290 358  1100
Age < 40 years, n (%) 98 (636) 37 (62) 61 (65)
Female, n (%) 110 (714) 35 (58) 75 (80)
Race, n (%)
White 110 (714) 42 (70) 68 (72)
Black 29 (188) 12 (20) 17 (18)
Other 15 (97) 6 (10) 9 (10)
Characteristics
Nicotine use, n (%)
Ever used 108 (701) 44 (73) 64 (68)
Current user 85 (552) 40 (67) 45 (48)
Former user 23 (149) 4 (7) 19 (20)
Nonuser 46 (299) 16 (27) 30 (32)
Body weight (kg), mean  SD 972  2480 1001  2761 954  2279
BMI (kg m
2), mean  SD 340  856 349  972 335  775
BMI 30–40, n (%) 58 (377) 17 (28) 41 (44)
BMI > 40, n (%) 43 (279) 22 (37) 21 (22)
Blood pressure (mmHg),
systolic/diastolic, mean  SD
125  139/79  10 125  142/79  96 125  139/80  102
HS disease duration (years),
mean  SD
119  952 120  911 118  982
Family history of HS, n (%) 43 (279) 20 (33) 23 (24)
HS-PGA, n (%)
Moderate or less 105 (682) 11 (18) 94 (100)
Severe/very severe 49 (318) 49 (82) 0
Hurley stage, n (%)
I/II (mild/moderate) 109 (708) 15 (25) 94 (100)
III (severe/very severe) 45 (292) 45 (75) 0
Prior therapies/medications, n (%)
Topical 76 (494) 30 (50) 46 (49)
Systemic 151 (981) 58 (97) 93 (99)
hsCRP
a (mg L
1), mean  SD 175  2602 (n = 117) 327  3679 (n = 43) 87  909 (n = 74)
VAS skin pain score,
b mean  SD 543  2646 659  2464 468  2496
PHQ-9 score
c (0–27), mean  SD 95  669 (n = 153) 110  649 85  666 (n = 93)
Modiﬁable cardiovascular risk factors
History of diabetes mellitus, n (%) 10 (65)
Current tobacco use, n (%) 85 (552)
BMI ≥ 30 and/or obesity, n (%) 103 (669)
TC ≥ 240 mg dL
1 or medical
history of hyperlipidaemia, n (%)
18 (117)
SBP ≥ 140 and/or DBP ≥ 90 mmHg
or history of hypertension, n (%)
396 (610)
Number of risk factors, n (%)
2 55 (357)
3 28 (182)
47 ( 4 5)
52 ( 1 3)
Percentages are based on patients with nonmissing values. BMI, body mass index; DBP, diastolic blood pressure; hsCRP, high-sensitivity C-
reactive protein; HS-PGA, HS Physician’s Global Assessment; PHQ, Patient Health Questionnaire; SBP, systolic blood pressure; TC, total cho-
lesterol; VAS, visual analogue scale.
aNormal range < 31m gL
1.
bVAS ranging from 0 (no pain) to 100 (worst pain).
cPHQ-9 scores for
depression severity: 0–4 none, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe.
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2 obesity
3 and
metabolic syndrome.
4 The objective of the current analysis
of patients with moderate-to-severe HS was to identify the
most common comorbidities, their prevalence according to
the level of HS disease burden (high vs. medium) and any
association between baseline characteristics and the risk for
the comorbidity. These patients, representing one of the
largest HS groups to be evaluated to date, were adults from
a 52-week, phase 2, randomised, double-blind, placebo-
controlled trial of adalimumab treatment,
5 who had at least
moderate disease [HS Physician’s Global Assessment (HS-
PGA) grade ≥ 3; 0–5 scale]. Additional inclusion/exclusion
criteria were published previously.
5
Baseline comorbidities were identiﬁed with patient reports
and medical histories. The following conditions were deﬁned:
hypertension, use of antihypertensive medication and/or self-
reported history; uncontrolled hypertension, systolic/diastolic
blood pressure (SBP/DBP) ≥ 140/≥ 90 mmHg; depression,
Patient Health Questionnaire 9 (PHQ-9) score ≥ 10;
6 morbid
obesity, body mass index (BMI) ≥ 40 kg m
2; hyperlipida-
emia, total cholesterol ≥ 240 mg dL
1; high HS disease bur-
den, HS-PGA > 3 and/or Hurley stage III; and medium HS
disease burden, HS-PGA ≤ 3 and Hurley stage II.
5
All patients with available baseline values were included
in this analysis. All statistical tests were two-sided and sig-
niﬁcant at 005. Associations between the most common
comorbidities and baseline characteristics were evaluated by
logistic regression. The odds ratio (OR) with 95% Wald
conﬁdence interval (CI) was provided. Final models were
chosen by stepwise selection with a P-value of 015 for
both entry and stay. Model selection was conducted per Ak-
aike information criteria and Bayesian information criteria,
which conﬁrmed the ﬁnal models selected by the stepwise
selection method.
Of the 154 patients in this analysis, 60 (390%) had high
HS disease burden and 94 (610%) had medium burden.
Mean high-sensitivity C-reactive protein (CRP) was almost
four times higher in the high vs. medium disease burden
groups (327m gL
1 vs. 87m gL
1). Combining self-report
and medical examination results, 396% of patients had
62
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Fig 1. Comorbidities in patients with
hidradenitis suppurativa: study population. (a)
Number and percentage of patients with
hypertension or hyperlipidaemia at baseline
(BL). (b) Prevalence of main comorbidities in
patients with high disease burden (HDB) vs.
medium disease burden (MDB). Hypertension
was identiﬁed by treatment with
antihypertensive medication and/or self-
reported history at BL. BMI, body mass index;
CI, conﬁdence interval; DBP, diastolic blood
pressure; OR, odds ratio; PHQ, Patient Health
Questionnaire; SBP, systolic blood pressure.
Correspondence 1563
 2014 The Authors. British Journal of Dermatology
Published by John Wiley & Sons Ltd on behalf of British Association of Dermatology
British Journal of Dermatology (2014) 171, pp1555–1609
© 2014 British Association of Dermatologistshypertension, 383% were morbidly obese and 481% had
depression. The incidence of modiﬁable cardiovascular risk
factors (Table 1) revealed that > 50% of patients were
smokers, overweight or had hypertension. Other cardiovascu-
lar risk factors included hyperlipidaemia (117%) and diabetes
mellitus (65%). Over one-third of patients (357%) had two
cardiovascular risk factors (Table 1).
Of the 403% of patients who had and/or were diagnosed
with hypertension, or were receiving antihypertensive medica-
tion (Fig. 1a), 53% had been diagnosed with hypertension,
and 31% had been both diagnosed and treated. Of the latter,
53% had reached the treatment goal (SBP/DBP < 140/
< 90 mmHg). Similarly, a minority with hyperlipidaemia
were both diagnosed and receiving medication (Fig. 1a).
The percentage of patients with morbid obesity or depres-
sion was 14% and 17% higher, respectively, in patients with
high vs. medium disease burden (Fig. 1b). The percentage of
patients with hypertension was 6% lower in patients with
high vs. medium disease burden (Fig. 1b).
Multiple logistic regression identiﬁed the most inﬂuential
factors for morbid obesity and depression. An association with
increased odds of morbid obesity was seen for high HS disease
burden (OR 213, 95% CI 100–453), and a trend towards
association was seen for depression (OR 174, 95% CI
082–368). Smoking was associated with reduced odds of
morbid obesity (OR 047, 95% CI 022–099). High HS dis-
ease burden (OR 212, 95% CI 104–431), female sex (OR
257, 95% CI 113–585) and smoking (OR 235, 95% CI
115–481) were associated with increased odds of
depression.
High HS disease burden was signiﬁcantly associated with
increased prevalence of morbid obesity and depression, but
not hypertension, partially contradicting a previous report that
also demonstrated the high prevalence of obesity and depres-
sion in patients with HS, but not signiﬁcant association
between disease severity and BMI or depression.
7 Our ﬁndings
are novel because we demonstrate that the magnitude of HS
disease burden appears to be correlated with the risk of
depression and morbid obesity, even after controlling for pos-
sible confounding variables.
Based on these ﬁndings, instructive parallels and differences
can be drawn between HS and psoriasis. Positive correlations
between psoriasis disease severity and obesity
8 and between
psoriasis disease severity and CRP elevation
9 have been dem-
onstrated. However, patients with psoriasis have lower CRP
levels,
9 and psoriasis disease severity correlates with hyperten-
sion prevalence.
8 More than just skin diseases, both HS and
psoriasis are systemic diseases associated with high systemic
inﬂammation and numerous comorbidities.
This analysis had several limitations. A cross-sectional
study cannot assess causality. This population may not
reﬂect the entire spectrum of patients with HS because it
was limited to clinical trial participants, for whom previous
treatment with tumour necrosis factor-a inhibitors, cardiac
insufﬁciency (New York Heart Association class III or
greater), active skin diseases and tumours were exclusion
criteria.
9 Meaningful correlations were difﬁcult to establish
due to the limited population size. Finally, patient-reported
prevalence of comorbidities is subject to recall bias.
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Familial pachyonychia congenita with
steatocystoma multiplex and multiple
abscesses of the scalp due to the p.Asn92Ser
mutation in keratin 17
DOI: 10.1111/bjd.13123
DEAR EDITOR, Pachyonychia congenita (PC) is a rare genoderma-
tosis transmitted as an autosomal dominant trait that is caused
by mutations in the differentiation-speciﬁc keratin genes KRT6a
(52%), KRT6b (3%), KRT16 (28%) or KRT17 (17%), which are
expressed in the nails, skin, oral mucosa, larynx, hair and
teeth.
1 Approximately 1000 patients with PC have been identi-
ﬁed, of whom 400 have been conﬁrmed genetically to have it.
Two subtypes have been classically described: PC-1
(Jadassohn–Lewandowsky type, OMIM#167200), caused by
mutations in KRT6a or KRT16, with predominant oral leucokera-
tosis and palmoplantar keratoderma; and PC-2 (Jackson–Lawler
type, OMIM#167210) resulting from mutations in KRT6b or
KRT17, with neonatal teeth, pili torti and multiple cysts.
2,3 The
presence of multiple sebaceous cysts [steatocystoma multiplex
(SM)] at puberty has been proposed to differentiate PC-2 from
PC-1,
2,3 but it is now recognized that there is a considerable
overlap between the two classical subtypes of PC, and a new
classiﬁcation based on the mutated keratin gene has now been
proposed (PC-6a, PC-6b, PC-16 and PC-17).
4,5
A 12-year-old girl presented with a painful inﬂammatory
plaque on her scalp, which had appeared recently without any
fever. She had a previous history of microcysts on her face
and multiple unsuccessful treatments for suspected fungal
infection of ﬁngernails and toenails. She had neonatal teeth.
Her mother had multiple steatocystomas on her face and trunk
(Fig. 1a), focal plantar keratoderma (Fig. 1b), normal nails
and a history of neonatal teeth. She had no history of
abscesses. Clinical examination of the scalp of the proband
showed multiple suppurative, well-circumscribed, alopecic
and cicatricial plaques on her vertex (Fig. 2a) and rough hair.
She had multiple microcysts on her face, predominantly on
her forehead (Fig. 2b); sebaceous cysts in the armpits; ophry-
ogenes-type keratosis pilaris of the eyebrows; pachyonychia of
all ﬁnger and toenails (Fig. 2c); and keratosis pilaris on both
thighs. The patient had no palmoplantar keratoderma. Histol-
ogy of the scalp revealed a cystic formation with no content,
lined with a thin eosinophilic epithelial lining, highly sugges-
tive of a sebaceous cyst (Fig. 2d). A non-perifollicular poly-
morphic inﬂammatory granuloma, rich in neutrophils,
lymphocytes and plasmocytes, was seen in the deep dermis.
Fungal examination was negative, and bacteriological cultures
yielded occasional colonies of Staphylococcus aureus. Microscopical
examination of the hair shaft showed normal thickness and a
longitudinal ﬁssure giving a ﬂat appearance (in places triangu-
(a) (b)
Fig 1. Clinical features of the patient’s
mother. (a) Multiple steatocystomas of the
face predominating on the forehead. (b) Focal
plantar keratoderma of the heel.
© 2014 British Association of Dermatologists British Journal of Dermatology (2014) 171, pp1555–1608
Correspondence 1565